Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-22
2011-11-29
Spivack, Phyllis G. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S406000, C514S448000
Reexamination Certificate
active
08067446
ABSTRACT:
A method for treating a digestive ulcer of the small intestine or stomach is disclosed with a non-purine xanthine oxidase inhibitor that is a carboxylic acid compound, wherein the non-purine xanthine oxidase inhibitor is a carboxylic acid compound of formula (I) or its salt and wherein the terms of formula (I) are herein defined:
REFERENCES:
patent: 5614520 (1997-03-01), Kondo et al.
patent: 5843969 (1998-12-01), Ota et al.
patent: 6015829 (2000-01-01), Ishibuchi et al.
patent: 2007/0275950 (2007-11-01), Miyata et al.
patent: 2008/0027048 (2008-01-01), Miyata et al.
patent: 57 85379 (1982-05-01), None
patent: 59 95272 (1984-06-01), None
patent: 92 09279 (1992-06-01), None
patent: 96 31211 (1996-10-01), None
patent: 98 18765 (1998-05-01), None
patent: 2006 022374 (2006-03-01), None
patent: 2006 022375 (2006-03-01), None
Karnam et al., Current Treatment Options in Gastroenterology, 4(1), (Feb. 1, 2001), pp. 15-21.
Lazarotos et al., European Journal of Pharmacology, (Feb. 9, 2001), 413(1), pp. 121-129.
Huh, Keun et al., “The Effect of Rebamipide on Gastric Xanthine Oxidase Activity and Type Conversion in Ethanol-Treated Rats”, Free Radical Biology and Medicine, Elsevier, Science Inc., vol. 20, No. 7, pp. 967-971, (1996).
Dodo, Kenjiro et al., “Kyoketsu Saikanryu-Ammonia Fuka Rat no Kyusei Inenmaku Byohen (AGML) no Hassei ni Taisuru Troxipide no Yokusei Koka”, Folia Pharmacologica Japonica, vol. 104, pp. 313-323, 1994, (with partial English translation).
Basivireddy, Jayasree et al., “Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes”, Biochemical Pharmacology, Elsevier, vol. 65, No. 4, pp. 683-695, (2003).
Khosravan, Reza et al., “Pharmacokinetic Interactions of Concomitant Administration of Febuxostat and NSAIDs”, J Clin Pharmacol., vol. 46, No. 8, pp. 855-866, (2006).
Naito, Yuji et al., “Role of Oxygen Radical and Lipid Peroxidation in Indomethacin-Induced Gastric Mucosal Injury”, Digestive Diseases and Sciences, vol. 43, No. 9, pp. 30S-34S (1998).
Zahavi, Ilan et al., “Oxygen Radical Scavengers are Protective Against Indomethacin-Induced Intestinal Ulceration in the Rat”, Journal of Pediatric Gastroenterology Nutrition, vol. 21, No. 2, pp. 154-157, (1995).
Salim, Aws S. et al., “Role of Free Radical Scavengers in the Management of Refractory Duodenal Ulceration”, Journal of Surgical Research, vol. 56, No. 1, pp. 45-52, (1994).
McAlindon, M E et al., “Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers” Gut, vol. 38, pp. 518-524, (1996).
Moorhouse, P. Christopher et al., “Allopurinol and oxypurinol are hydroxyl radical scavengers”, FEBS Letters 04481, vol. 213, No. 1, pp. 23-28, (1987).
Zhonghui Wen, et al., “Inflammatory Bowel Disease: Autoimmune or Immune-Mediated Pathogenesis”, Clinical and Developmental Immunology, Sep./Dec. 2004, vol. 11, (3/4), pp. 194-204.
Seigo Ishibuchi, et al., “Synthesis and Structure—Activity Relationships of 1-Phenylpyrazoles as Xanthine Oxidase Inhibitors”, Bioorganic & Medicinal Chemistry Letters 11 (2001) 879-882.
Koji Takeuchi, et al., “Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage” Clinica Chimica Acta 411 (2010) 459-466.
S. J. Kontrurek, et al., “Prostaglandins and Ulcer Healing” Journal of Physiology and Pharmacology, 2005, 56, Supp 5, 5-31.
Arthur Kaser, et al., “Inflammatory Bowel Disease”, Annu. Rev. Immunol. 2010.28:573-621.
Y.H. Kho, et al., “Pharmacotherapeutic Options in Inflammatory Bowel Disease: An Update”, Pharmacy World & Science, vol. 23, No. 1 (2001).
Jeffrey J. Ares, et al., “Gastroprotective Agents for the Prevention of NSAID-Induced Gastropathy”, Current Pharmaceutical Design, vol. 4, No. 1, XP-002952634, Jan. 1, 1998, pp. 17-36.
Oa Al-Swayeh, et al., “Sucralfate attennuates gastric mucosal lesions and increased vascular permeability induced by ischaemia and reperfusion in rats”, Journal of Gastroenterology and Hepatology, vol. 12, No. 7, XP-002586723, Jul. 1997, pp. 481-489.
Yuichiro J. Suzuki, et al., “Antioxidant Properties of Nitecapone (OR-462)”, Free Radical Biology & Medicine, vol. 13, No. 5, XP-023523273, Nov. 1, 1992, pp. 517-525.
Fukuda Mari
Ikeda Ken
Kawakami Masakatsu
Keto Yoshihiro
Sato Junji
Astellas Pharma Inc.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Spivack Phyllis G.
LandOfFree
Methods for treating an ulcer of the small intestine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating an ulcer of the small intestine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating an ulcer of the small intestine and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4276547